Exidavnemab

DB19452InvestigationalProtein Based Therapies

Exidavnemab is under investigation in clinical trial NCT06671938 (Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease).

Mechanism: Pharmacologically active on Alpha-synuclein
Curator reviewed
Also known as: Immunoglobulin g4 (226-proline), anti-(human .alpha.-synuclein) (human-mus musculus monoclonal pr-1808164 .gamma.4-chain), disulfide with human-mus musculus monoclonal pr-1808164 .kappa.-chain, dimer

Resolves to

Compound

UNIIBHV7HS9CF3CAS2438229-02-6

Targets

P37840SNCA

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Exidavnemab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account